Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

In Friday's pre-market session, several healthcare stocks saw significant movement. Alpha Tau Medical, NeuBase Therapeutics, Avalo Therapeutics, Timber Pharmaceuticals, AcelRx Pharmaceuticals, and TRACON Pharma all saw increases in their share prices. Conversely, Athersys, CervoMed, Bone Biologics, Scilex Holding, Predictive Oncology, and NRX Pharmaceuticals all experienced decreases.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 1:06 pm

NRX Pharmaceuticals reported Q2 losses of $(0.12) per share, beating the analyst consensus estimate of $(0.14) by 14.29%. However, this represents a 9.09% increase in losses compared to the same period last year.

Portfolio Pulse from mahesh@benzinga.com

August 14, 2023 | 8:46 pm

NRX Pharmaceuticals (NASDAQ:NRXP) is set to release its latest quarterly earnings report on Monday, 2023-08-14. Analysts estimate an earnings per share (EPS) of $-0.14. The company's past performance shows a pattern of EPS misses followed by share price increases. The stock is currently trading at $0.31, down 58.05% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 2:01 pm

On Wednesday, 155 companies set new 52-week lows. The largest company by market cap to set a new 52-week low was Estee Lauder Cos (NYSE:EL). The smallest company by market cap to set a new 52-week low was SenesTech (NASDAQ:SNES). Siyata Mobile (NASDAQ:SYTA)'s stock fell the most, as it traded down 7658.62% to reach a new 52-week low. Sutro Biopharma (NASDAQ:STRO) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 4:27 pm

On Monday, 149 companies reached new 52-week lows. The largest company by market cap to hit a new 52-week low was NextEra Energy (NYSE:NEE), while the smallest was Esports Entertainment (NASDAQ:GMBL). Bionano Genomics (NASDAQ:BNGO) saw the most pronounced move, with shares trading down 842.14% to hit its new 52-week low. Northwest Natural Hldg (NYSE:NWN) shares gained 0.0%, rebounding after it reached its 52-week low.

Portfolio Pulse from Benzinga Insights

August 07, 2023 | 4:13 pm

NRx Pharmaceuticals has announced the licensure of a US patent to support the use of NRX-101 for chronic pain. This development could potentially expand the application of NRX-101 beyond its current use.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:48 am

In Tuesday's after-market session, several health care stocks saw significant movement. Gainers included 9 Meters Biopharma (NASDAQ:NMTR), ViewRay (NASDAQ:VRAY), Plus Therapeutics (NASDAQ:PSTV), PAVmed (NASDAQ:PAVM), CollPlant Biotechnologies (NASDAQ:CLGN), and NRX Pharmaceuticals (NASDAQ:NRXP). Losers included INVO Bioscience (NASDAQ:INVO), Adial Pharmaceuticals (NASDAQ:ADIL), Etao International Co (NASDAQ:ETAO), Fresh Tracks Therapeutics (NASDAQ:FRTX), Myomo (AMEX:MYO), and ThermoGenesis Holdings (NASDAQ:THMO).

Portfolio Pulse from Benzinga Insights

July 25, 2023 | 9:32 pm

During Monday's pre-market session, several health care stocks saw significant movement. PaxMedica, Precigen, Moleculin Biotech, Vivos Therapeutics, NRX Pharmaceuticals, and Virpax Pharmaceuticals all saw increases, with PaxMedica leading the gainers with a 24.3% increase. On the other hand, Kodiak Sciences, Infinity Pharmaceuticals, BioCardia, ViewRay, Verrica Pharmaceuticals, and Puma Biotechnology all experienced decreases, with Kodiak Sciences leading the losers with a 56.7% decrease.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 1:06 pm

In Wednesday's after-market session, several healthcare stocks saw significant movement. Gainers included NRX Pharmaceuticals, Orchestra BioMed Hldgs, NeuBase Therapeutics, Matinas BioPharma Hldgs, Minerva Surgical, and Omega Therapeutics. Losers included CryoPort, Petros Pharma, Healthcare Triangle, Redhill Biopharma, Connect Biopharma Hldgs, and Freeline Therapeutics.

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 9:38 pm

NRX Pharmaceuticals announced a $6.28 million registered direct offering, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 7:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.